Adherence to Annual Lung Cancer Screening Within the Veterans Health Administration Lung Cancer Screening Demonstration Project

Brasher, Paul Bradley; Tanner, Nichole T.; Yeager, Derik; Silvestri, Gerard A.

doi:10.1016/j.chest.2018.08.576

Cited by 12 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The low rates of imaging may also be a function of low adherence to recommendations after LDCT scan in the community compared with clinical trials' LDCT scan. 2,4,[18][19][20][21] This may also account for the lower rates of follow-up testing of follow-up vs initial LDCT examinations compared with NLST data in which rates were similar after the second LDCT and lower for the third LDCT scan. 2 Our study has several limitations.…”

Section: Discussionmentioning

confidence: 99%

Use of Imaging and Diagnostic Procedures After Low-Dose CT Screening for Lung Cancer

Nishi

Zhou

Okereke

et al. 2020

Chest

View full text Add to dashboard Cite

BACKGROUND: Clinical trials have demonstrated a mortality benefit from lung cancer screening by low-dose CT (LDCT) in current or past tobacco smokers who meet criteria. Potential harms of screening mostly relate to downstream evaluation of abnormal screens. Few data exist on the rates outside of clinical trials of imaging and diagnostic procedures following screening LDCT. We describe rates in the community setting of follow-up imaging and diagnostic procedures after screening LDCT. METHODS:We used Clinformatics Data Mart national database to identify enrollees age 55 to 80 year who underwent screening LDCT from January 1, 2016, to December 31, 2016. We assessed rates of follow-up imaging (diagnostic chest CT scan, MRI, and PET) and follow-up procedures (bronchoscopy, percutaneous biopsy, thoracotomy, mediastinoscopy, and thoracoscopy) in the 12 months following LDCT for lung cancer screening. We also assessed these rates in an age-, sex-, and number of comorbidities-matched population that did not undergo LDCT to estimate rates unrelated to the screening LDCT. We then reported the adjusted rate of follow-up testing as the observed rate in the screening LDCT population minus the rate in the non-LDCT population.RESULTS: Among 11,520 enrollees aged 55 to 80 years who underwent LDCT in 2016, the adjusted rates of follow up 12 months after LDCT examinations were low (17.7% for imaging and 3.1% for procedures). Among procedures, the adjusted rates were 2.0% for bronchoscopy, 1.3% for percutaneous biopsy, 0.9% for thoracoscopy, 0.2% for mediastinoscopy, and 0.4% for thoracotomy. Adjusted rates of follow-up procedures were higher in enrollees undergoing an initial screening LDCT (3.3%) than in those after a second screening examination (2.2%).CONCLUSIONS: In general, imaging and rates of procedures after screening LDCT was low in this commercially insured population.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Imaging and Diagnostic Procedures After Low-Dose CT Screening for Lung Cancer

Nishi

Zhou

Okereke

et al. 2020

Chest

View full text Add to dashboard Cite

show abstract

“…The length of follow-up ranged from 12 to 18 months, with 1 study 18 reporting data to 36 months. Only 3 studies 14,27,29 reported their funding sources.…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

“…Thirteen studies [12][13][14][15][16][17]19,20,22,23,[27][28][29] (87%) confirmed screening adherence through medical records or large database records. However, 12 studies 12,[14][15][16][17][18]20,22,23,25,27,28 (80%) did not have a follow-up time that was long enough to adequately assess periodic adherence beyond 1 year. All of the studies reported loss-to-follow-up rates greater than 20% (eTable 2 in the Supplement).…”

Section: Risk Of Bias Within Studiesmentioning

confidence: 99%

Patient Adherence to Screening for Lung Cancer in the US

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the VA Lung Cancer Screening Demonstration Project, a VHA program that provided resources in a real-world setting to evaluate lung cancer screening, lung cancer screening follow-up adherence (with a broader follow-up time period of 1 day to 18 months) was found to be 82.2% [29]. Adherence rates to annual repeat lung screening in the real-world setting have been reported between 59% and 85.7% [24,30,31]. A pooled metaanalysis showed 55% adherence across all follow-up periods (ranging from 12 to 36 months) [32].…”

Section: Discussionmentioning

confidence: 99%

Association of Rurality With Annual Repeat Lung Cancer Screening in the Veterans Health Administration

Spalluto

Lewis

Samuels

et al. 2022

Journal of the American College of Radiology

View full text Add to dashboard Cite

Lung, and Blood Institute (K12HL137943) (Drs Lewis and Roumie). Drs Spalluto, Lewis, and Callaway-Lane serve on the Steering Committee for this VAMC lung screening program. Drs Lewis and Callaway-Lane are clinical codirectors of the clinical lung cancer screening program. Neither receives financial compensation for these roles. Dr Yankelevitz is a named inventor on a number of patents and patent applications relating to the evaluation of diseases of the chest, including measurement of nodules. Some of these, which are owned by the Cornell Research Foundation (CRF), are nonexclusively licensed to General Electric. As an inventor of these patents, Dr Yankelevitz is entitled to a share of any compensation CRF may receive from its commercialization of these patents. He is also an equity owner in Accumetra, a privately held technology company committed to improving the science and practice of image-based decision making. Dr Yankelevitz also serves on the advisory board of GRAIL. Dr Henschke is president and serves on the board of the Early Diagnosis and Treatment Research Foundation. She receives no compensation from the foundation. The foundation was established to provide grants for projects, conferences, and public databases for research on early diagnosis and treatment of diseases. Dr Henschke is also a named inventor on a number of patents and patent applications relating to the evaluation of pulmonary nodules on CT scans of the chest, which are owned by CRF. Since 2009, Dr Henschke has not accepted any financial benefit from these patents, including royalties and any other proceeds related to the patents or patent applications owned by CRF. All other authors state that they have no conflict of interest related to the material discussed in this article. All authors are employees.† Deceased.

show abstract

Adherence to Annual Lung Cancer Screening Within the Veterans Health Administration Lung Cancer Screening Demonstration Project

Cited by 12 publications

References 0 publications

Use of Imaging and Diagnostic Procedures After Low-Dose CT Screening for Lung Cancer

Use of Imaging and Diagnostic Procedures After Low-Dose CT Screening for Lung Cancer

Patient Adherence to Screening for Lung Cancer in the US

Association of Rurality With Annual Repeat Lung Cancer Screening in the Veterans Health Administration

Contact Info

Product

Resources

About